-
Mashup Score: 21Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels - 6 month(s) ago
This meta-analysis evaluates whether adding docetaxel to testosterone suppression plus curative local treatment was associated with decreased mortality among patients with high-grade, localized or locally advanced, nonmetastatic prostate cancer with low serum levels of prostate-specific antigen…
Source: jamanetwork.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1
Drs. Bossi and Wallis break down the results of the PEACE-1 study presented as a late-breaking abstract at the ASCO 2023 Annual Meeting.
Source: GU Oncology NowCategories: Latest Headlines, Partners & KOLsTweet-
The PEACE-1 study results on ADT and #docetaxel with abiraterone acetate plus prednisone are discussed by @AlbertoBossial and @WallisCJD in our latest interview. Watch now: https://t.co/D1Kafb7G0E https://t.co/AP6dHxzW8l
-
-
Mashup Score: 0
Is there an alternative regimen to BCG for NMIBC? According to a recent trial, the combination of intravesical gemcitabine and docetaxel may.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
David Ambinder, MD (@SimplyUroMD) discusses the recent randomized trial published in @JAMANetworkOpen on the combination of intravesical #gemcitabine and #docetaxel that may be an effective alternative to BCG for high-risk NMIBC. Read more: https://t.co/FUK77zLgQC https://t.co/0LI8sb6vEl
-
-
Mashup Score: 0Roundtable Discussion: Dorff Reviews Factors for Selecting Chemotherapy and Other Later-Line mCRPC Treatments - 12 month(s) ago
During a Targeted Oncology™ Case-Based Roundtable™ event, Tanya B. Dorff, and participants, discussed the case of a patient with metastatic castration-resistant prostate cancer who has already received enzalutamide and docetaxel.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this article, @TDorffOnc discussed a case of metastatic castration-resistant prostate cancer in a patient who has already received #enzalutamide and #docetaxel. #mcrpc #pcsm | @cityofhope https://t.co/cRG6bvGPTk
-
-
Mashup Score: 0
A phase 2 dose expansion cohort which received the investigational agent abequolixron plus docetaxel showed clinical responses in patients with non–small cell lung cancer and small cell lung cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Abequolixron led to early clinical activity in combination with #docetaxel in heavily-pretreated patients with #NSCLC and #SCLC. #lcsm | @FoxChaseCancer https://t.co/u1zd2fiMGJ
-
-
Mashup Score: 0
Options needed since it is not uncommon to encounter cisplatin ineligibility, researchers say
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
Adding #docetaxel to RT improved survival outcomes in cisplatin-ineligible patients w/ locally advanced head & neck squamous cell #carcinoma, reported Dr. Kumar Prabhash. "It should not be declared the lone standard." --@drlorenmell & @StuartWongMD1 https://t.co/hFPSBmnjzd
-
-
Mashup Score: 0November 2022 Journal Issue - 1 year(s) ago
Read articles from the November 2022 issue of the GU Oncology Now Journal.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Be sure to check out the latest issue of GU Oncology Now, including our profile on Bradley A. McGregor, MD @BradMcG04 and trial results of microparticle #docetaxel for high-risk #NMIBC. Read all the articles from our November issue here: https://t.co/IAWpXnM2vn https://t.co/065pRoAHXt
-
-
Mashup Score: 1Episode 202: The Uromigos Paper of the Month—Docetaxel and Continuous Enzalutamide in CRPC - 2 year(s) ago
The Uromigos chat with Axel Merseburger, MD, PhD, about his paper on continuing enzalutamide with docetaxel for the treatment of CRPC.
Source: GU Oncology NowCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Listen to the latest @Uromigos podcast, where @amerseburger discusses his paper on continuing #enzalutamide with #docetaxel for the treatment of castration-resistant #prostatecancer. https://t.co/EUTAZ2Fk20
-
-
Mashup Score: 0Sotorasib superior to docetaxel in KRAS G12C–mutated NSCLC - 2 year(s) ago
In its first randomized, phase 3 comparison trial, the first-in-class agent sotorasib held its own against the standard of care docetaxel.
Source: www.mdedge.comCategories: Hem/Oncs, Latest HeadlinesTweet-
#Sotorasib superior to #Docetaxel in KRAS G12C–mutated #NSCLC! 👉https://t.co/iUVHN5qZXr @MDedgeHemOnc @NeilOsterweil #KRAS @SarahCannonDocs https://t.co/pC2IVXpd0e
-
-
Mashup Score: 0
Significant improvements in progression-free survival were seen with sotorasib compared with docetaxel in patients with KRAS G12C–mutated non–small cell lung cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Significant improvements in progression-free survival were seen with #sotorasib compared with #docetaxel in patients with KRAS G12C–mutated non–small cell lung cancer. #nsclc #lcsm #ESMO22 | @MLJohnsonMD2 @SarahCannonDocs https://t.co/HNHshMqCDT
-
#Docetaxel use associated with significant reduction in prostate cancer death in very poor prognostic group @BrighamWomens @jamanetworkopen https://t.co/Hg50ugc5Nm https://t.co/QDGffkVWbs